
P R E S S R E L E A S E

Ypsomed to increase production capacity

Burgdorf, April 24, 2015, 7:00 a.m. – The long-standing partnership between the French pharmaceutical group Sanofi and the Ypsomed Group will be bolstered by a new major project: starting in late 2016, Ypsomed plans to manufacture components for injection systems on an additional dedicated production line. The additional annual capacity will be in the double-digit millions.

Ypsomed has been manufacturing injection systems for the French pharmaceutical group for over twenty years. The high production quality and unparalleled expertise in the field of injection systems were deciding factors in awarding an additional production line to Ypsomed. The work to prepare the new production facilities will start immediately. These facilities will be capable of manufacturing several versions of injection systems and Ypsomed will deliver millions of pen components as a contract manufacturer to Sanofi. The production is planned to start in the second half of 2016.

"Ypsomed is very pleased to receive Sanofi's continued trust. This attests to our production and service quality levels. The cooperation between the two companies will be strengthened and enhanced for many more years," explains Ypsomed CEO Simon Michel regarding this new success.

For further information, please contact Benjamin Overney, Head of Investor & Public Relations at Ypsomed Holding AG, by phone at +41 34 424 41 59 or by email (benjamin.overney@ypsomed.com).

About the Ypsomed Group

The Ypsomed Group is the leading developer and manufacturer of injection systems for self-medication and a renowned diabetes specialist with 30 years of experience. Founded in 2003 from the well-known company Disetronic Medical Systems, today it offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disorders, infertility, oncology and other therapeutic areas. Ypsomed is regarded as a leader in innovation and technology and is the preferred partner of pharmaceutical and biotech companies in the self-medication field. Ypsomed has established itself with the umbrella brands mylife™ Diabetscare and YDS™ Ypsomed Delivery Systems in retailing and in business-to-business trading respectively. Under the brand name mylife™ Diabetscare, Ypsomed offers patients an extensive range of self-manufactured products or commercial products for the treatment of diabetes. The range from YDS™ reflects the many years of experience and competence in the field of injection systems. With an innovative and patent-protected product portfolio of pen systems and autoinjectors, which can be adapted to customer requirements, and contract development and manufacturing, Ypsomed provides customer orientated product and service solutions to pharmaceutical and biotech companies worldwide. Ypsomed has its headquarters in Burgdorf in Switzerland and owns several manufacturing sites in Switzerland and in the Czech Republic. Ypsomed has its own subsidiaries throughout Europe and works with leading, independent marketing partners worldwide. The Ypsomed Group has around 1,100 employees.